Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line
- PMID: 12359058
- PMCID: PMC5927134
- DOI: 10.1111/j.1349-7006.2002.tb02481.x
Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line
Abstract
We isolated a paclitaxel-resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700-fold resistance to paclitaxel and cross-resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized alpha- and beta-tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P-glycoprotein (P-gp) and lung resistance-related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P-gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclohexane (N-5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N-5228 inhibited photoaffinity labeling of P-gp by [(3)H]azidopine, suggesting that N-5228 could bind to P-gp directly and could be a substrate of P-gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P-gp-mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3,4-dimethoxy functionalities, which have moderate electron-donating ability. These findings may provide valuable information for the development of P-gp-mediated MDR-reversing agents.
Similar articles
-
Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.Aktuelle Urol. 2003 Jul;34(4):250-2. doi: 10.1055/s-2003-41608. Aktuelle Urol. 2003. PMID: 14566676
-
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.J Surg Res. 2001 Aug;99(2):179-86. doi: 10.1006/jsre.2001.6126. J Surg Res. 2001. PMID: 11469885
-
Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.J Urol. 1992 Aug;148(2 Pt 1):441-5. doi: 10.1016/s0022-5347(17)36624-7. J Urol. 1992. PMID: 1353119
-
Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.Biochem Pharmacol. 1992 Jan 9;43(1):103-7. doi: 10.1016/0006-2952(92)90667-8. Biochem Pharmacol. 1992. PMID: 1346493 Review.
-
P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design.Curr Top Med Chem. 2016;16(22):2484-508. doi: 10.2174/1568026616666160212123814. Curr Top Med Chem. 2016. PMID: 26873188 Review.
Cited by
-
Nanomedicine therapeutic approaches to overcome cancer drug resistance.Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79. doi: 10.1016/j.addr.2013.09.019. Epub 2013 Oct 10. Adv Drug Deliv Rev. 2013. PMID: 24120656 Free PMC article. Review.
-
Cepharanthine inhibits migration, invasion, and EMT of bladder cancer cells by activating the Rap1 signaling pathway in vitro.Am J Transl Res. 2024 May 15;16(5):1602-1619. doi: 10.62347/WDFF7432. eCollection 2024. Am J Transl Res. 2024. PMID: 38883391 Free PMC article.
-
Bioactivities and Medicinal Value of Solanesol and Its Accumulation, Extraction Technology, and Determination Methods.Biomolecules. 2019 Aug 2;9(8):334. doi: 10.3390/biom9080334. Biomolecules. 2019. PMID: 31382471 Free PMC article. Review.
-
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.Chin J Cancer. 2012 Feb;31(2):100-9. doi: 10.5732/cjc.011.10326. Epub 2012 Jan 9. Chin J Cancer. 2012. PMID: 22237039 Free PMC article. Review.
-
Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.J Biomed Biotechnol. 2011;2011:281651. doi: 10.1155/2011/281651. Epub 2011 Jun 30. J Biomed Biotechnol. 2011. PMID: 21765632 Free PMC article.
References
-
- ) Bremnes , R. M. , Sundstrom , S. , Vilsvik , J. and Aasebo , U.Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited‐stage small‐cell lung cancer . J. Clin. Oncol. , 19 , 3532 – 3538 ( 2001. ). - PubMed
-
- ) Riccardi , A. , Pugliese , P. , Danova , M. , Brugnatelli , S. , Grasso , D. , Giordano , M. , Bernardo , G. , Giardina , G. , Fava , S. , Montanari , G. , Pedrotti , C. , Trotti , G. , Rinaldi , E. , Poli , M. A. and Tinelli , C.A phase II study of sequential 5‐fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01) . Br. J. Cancer , 85 , 141 – 146 ( 2001. ). - PMC - PubMed
-
- ) Prince , H. M. , Rischin , D. , Quinn , M. , Allen , D. , Planner , R. , Neesham , D. , Gates , P. and Davison , J.Repetitive high‐dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study . Gynecol. Oncol. , 81 , 216 – 224 ( 2001. ). - PubMed
-
- ) Hurwitz , C. A. , Strauss , L. C. , Kepner , J. , Kretschmar , C. , Harris , M. B. , Friedman , H. , Kun , L. and Kadota , R.Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study . J. Pediatr. Hematol. Oncol. , 23 , 277 – 281 ( 2001. ). - PubMed
-
- ) Haas , N. , Roth , B. , Garay , C. , Yeslow , G. , Entmacher , M. , Weinstein , A. , Rogatko , A. , Babb , J. , Minnitti , C. , Flinker , D. , Gillon , T. and Hudes , G.Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone‐refractory prostate cancer . Urology , 58 , 59 – 64 ( 2001. ). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous